On July 8, 2022, an email containing the following information was sent to Meridian Bioscience,
Inc.s Life Science segment customers to address potential questions in connection with that certain Agreement and Plan of Merger, dated as of July 7, 2022, by and among, SD Biosensor, Inc., Columbus Holding Company, Madeira Acquisition
Corp., and Meridian Bioscience, Inc. (the Merger Agreement):
SD Biosensor/SJL Acquisition
Email to Meridian Bioscience Inc.s Life Science Segment Customers
We are excited to announce the news that Meridian Bioscience, Inc. has entered into an agreement to be acquired by SD Biosensor and SJL Partners of South
Korea.
Please see attached our official press release.
This transaction will provide Meridian tremendous benefit as it will help us increase our scale, expand our markets, strengthen our product offerings and
accelerate innovation.
|
|
|
We will not have any changes in our day-to-day business as we remain committed to delivering world class
life science products that our customers depend on. |
|
|
|
All existing Meridian Life Science and Bioline customer contracts, orders and agreements will convey as they
currently exist. |
|
|
|
There will be no changes to any logistics, manufacturing sites, labeling, documents or anything that can
impact you as a customer. |
|
|
|
Meridian Life Science, Inc. and Bioline, Inc. will remain as independent legal entities and will not be
integrated into SD Biosensor. |
In conclusion, this acquisition will not represent any changes that can impact our business
together.
We appreciate your business and look forward to a continued partnership and a strong future together.
Additional Information and Where to Find It
In connection with the proposed transaction, the Company intends to file relevant information with the SEC, including a proxy statement on Schedule 14A. This
communication is not a substitute for the Proxy Statement or for any other document that the Company may file with the SEC and send to its shareholders in connection with the proposed transaction. Promptly after filing its definitive proxy statement
with the SEC, the Company will mail the definitive proxy statement to each shareholder entitled to vote at the special meeting relating to the transaction. THE COMPANYS SHAREHOLDERS ARE URGED TO CAREFULLY READ THE PROXY STATEMENT (INCLUDING
ANY AMENDMENTS OR SUPPLEMENTS THERETO AND ANY DOCUMENTS INCORPORATED BY REFERENCE THEREIN) AND ANY OTHER RELEVANT DOCUMENTS IN CONNECTION WITH THE TRANSACTION THAT THE COMPANY WILL FILE WITH THE SEC WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL
CONTAIN IMPORTANT INFORMATION ABOUT THE TRANSACTION AND THE PARTIES TO THE TRANSACTION. The definitive proxy statement, the preliminary proxy statement, other relevant materials in connection with the transaction (when they become available) and any
other documents filed by the Company with the SEC, may be obtained free of charge at the Companys website (www.investor.meridianbioscience.com) or the SECs website (www.sec.gov). These documents may also be obtained free of
charge from the Company by requesting them by mail at 3471 River Hills Drive, Cincinnati, OH 45244, Attention: Charlie Wood, Vice President Investor Relations, or by email at mbi@meridianbioscience.com.
Participants in the Solicitation
The Company and its
directors and executive officers may be deemed, under SEC rules, to be participants in the solicitation of proxies from the Companys shareholders in connection with the transaction. You may obtain information about the Companys executive
officers and directors in the Companys definitive proxy statement for its 2022 annual meeting of shareholders, which was filed with the SEC on December 15, 2021. To the extent holdings of such participants in the Companys securities
are not reported, or have changed since the amounts described in the proxy statement for the 2022 annual meeting of shareholders, such changes have been reflected on the Initial Statements of Beneficial Ownership on Form 3 or Statements of Change in
Ownership on Form 4 filed with the SEC. These documents may be obtained free of charge at the Companys website (www.investor.meridianbioscience.com) or the SECs website (www.sec.gov). Other information regarding the
participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, will be contained in the Proxy Statement and other relevant materials to be filed with the SEC in connection with the
proposed transaction when they become available.